期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 64, 期 10, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00397-20
关键词
metallo-beta-lactamase; treatment; pharmacology; drug development; metalloenzymes
资金
- UKRI Innovation Fellowship through the North West MRC Scheme in Clinical Pharmacology
- Roche Pharma
- F2G
- Astellas Pharma
- Spero Therapeutics
- Antabio
- Allecra
- Bugworks
- NAEJA-RGM
- Medical Research Council
- National Institute of Health Research
- FDA
- European Commission
- MRC [MR/N025989/1, MR/R016895/1] Funding Source: UKRI
Modern medicine is threatened by the global rise of antibiotic resistance, especially among Gram-negative bacteria. Metallo-beta-lactamase (MBL) enzymes are a particular concern and are increasingly disseminated worldwide, though particularly in Asia. Many MBL producers have multiple further drug resistances, leaving few obvious treatment options. Nonetheless, and more encouragingly, MBLs may be less effective agents of carbapenem resistance in vivo, under zinc limitation, than in vitro. Owing to their unique structure and function and their diversity, MBLs pose a particular challenge for drug development. They evade all recently licensed beta-lactam-beta-lactamase inhibitor combinations, although several stable agents and inhibitor combinations are at various stages in the development pipeline. These potential therapies, along with the epidemiology of producers and current treatment options, are the focus of this review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据